Inflammatory breast cancer: 14 things to know

Study Indicates That Exercise Can Help Colon Cancer Survivors Live As Long As Matched Individuals

Just a moment...

This request seems a bit unusual, so we need to confirm that you're human. Please press and hold the button until it turns completely green. Thank you for your cooperation!

Press and Hold

Press and hold the button

If you believe this is an error, please contact our support team.

167.71.87.121 : 5776d480-6f94-408b-95f9-4025a841

Can Exercise Help Colon Cancer Survivors Live Longer?

A new study finds that exercise significantly boosts longevity in colon cancer survivors. Data analyzed from two trials reveals that those who exercised 18+ MET-hours per week had better survival rates, even surpassing a matched general population. This emphasizes the critical role of physical activity in improving long-term prognosis for colon cancer patients.

While we all know that exercise is beneficial for overall health, a new study has found that it can also boost longevity in colon cancer survivors.A new study Cancer People who have colon cancer often have higher rates of premature mortality than people in the general population with matched characteristics such as age and sex. In order to understand whether exercise will reduce this disparity, the researchers looked at the data from two posttreatment trials in patients with stage 3 colon cancer, with a total of 2,875 patients who self-reported physical activity after cancer surgery and chemotherapy. They also analyzed the data on a matched general population from the National Center for Health Statistics.The physical activity of all participants was based on metabolic equivalent (MET) hours per week. 150 minutes of moderate-intensity exercise per week is often recommended which translates into approximately 8 MET-hours/week.In the first trial (CALGB 89803), colon cancer survivors who were still alive three years after treatment and exercised very little (In the second trial (CALGB 80702), among survivors who were alive at three years, those with low activity (When researchers combined data from both trials, they analyzed 1,908 patients who were alive and had no cancer recurrence three years after treatment. Survivors who exercised less than 3.0 MET-hours/week had a 3.1% lower survival rate over the next three years compared to the general population.

Survivors who exercised 18.0 or more MET-hours/week actually had a 2.9% higher survival rate than the general population. This hints that colon cancer survivors who remained tumor-free and engaged in regular exercise not only matched but even surpassed the survival rates of the general population.

How Important Is Genetic Testing In Detecting Cancers Early

"This new information can help patients with colon cancer understand how factors that they can control—their physical activity levels—can have a meaningful impact on their long-term prognosis. Also, medical and public health personnel and policymakers are always seeking new ways to communicate the benefits of a healthy lifestyle. Quantifying how physical activity may enable a patient with colon cancer to have a survival experience that approximates their friends and family without cancer could be a simple but powerful piece of information that can be leveraged to help everyone understand the health benefits of physical activity," Justin C. Brown, PhD, lead author, Pennington Biomedical Research Center and the Louisiana State University Health Sciences Center said in a statement.

Cetuximab Plus Chemotherapy May Improve Colorectal Cancer Outcomes

When combined with chemotherapy, cetuximab shows promising efficacy for optimizing treatment strategies for patients with metastatic colorectal cancer.

Cetuximab (Erbitux) plus chemotherapy showed higher progression-free survival (PFS) and overall survival (OS) for patients with metastatic colorectal cancer (mCRC), according to one study.

When combined with chemotherapy, cetuximab shows promising efficacy for optimizing treatment strategies for patients with metastatic colorectal cancer (mCRC).Image credit: Chinnapong - stock.Adobe.Com

These findings offer valuable insights for optimizing mCRC treatment strategies. The systemic and meta-analysis was published in BMC Cancer.

"Monoclonal antibodies are effective therapeutic options in mCRC treatment," wrote the researchers of the study. "Cetuximab, an anti-EGFR monoclonal antibody, demonstrated a significant advancement in managing mCRC when combined with various chemotherapy regimens. When used in conjunction with chemotherapy, cetuximab had a better prognosis for patients with CRC who had metastases by improving both overall and progression-free survival."

Cetuximab was approved in 2004 to treat patients with advanced CRC that has spread to other parts of the body, making it the first monoclonal antibody approved to treat this type of cancer.2 In December 2024, the FDA approved encorafenib with cetuximab and mFOLFOX6 for mCRC with BRAF V600E mutation, based on BREAKWATER trial (NCT04607421) results.3

In this study, the researchers searched PubMed and Google Scholar for studies on mCRC treatment with anti-EGFR therapy.1 Primary outcomes included PFS and OS, standardized across studies. Data extraction was independently conducted by 2 reviewers, with discrepancies resolved through discussion. Study quality was assessed using the Newcastle–Ottawa Scale. Statistical analysis employed fixed- or random-effects models based on heterogeneity, with subgroup analysis and funnel plots used to assess bias.

A total of 25 studies were included in the analysis, with 3788 patients with mCRC, aged 18 to 77 years. Patients receiving cetuximab plus chemotherapy showed significantly improved PFS (HR, 0.79; 95% CI, 0.63–0.96, P < .01, I² = 38%) and OS (HR, 0.78; 95% CI, 0.60–0.91, P < .01, I² = 47%) compared with controls. Subgroup analysis of randomized controlled trials confirmed these benefits, with consistent HRs for PFS (HR, 0.77; 95% CI, 0.62–0.93) and OS (HR, 0.76; 95% CI, 0.61–0.88), reinforcing cetuximab's efficacy.

However, the researchers noted some limitations. First, small sample sizes in some studies may have influenced outcomes, and the inclusion of both retrospective and prospective studies could impact result accuracy. Second, methodological differences—such as study design, patient characteristics, treatment protocols, and follow-up periods—contributed to heterogeneity. Third, restricting the analysis to English-language publications introduces potential publication bias. Lastly, the findings relied on HRs, but not all studies reported these with corresponding confidence intervals, particularly for OS, which may have affected result reliability.

Despite these findings, the researchers believe the study demonstrated significant benefits of combining cetuximab with chemotherapy for patients with mCRC.

"The cetuximab-based therapy is associated with a substantial improvement in progression-free survival and overall survival compared to chemotherapy alone," wrote the researchers. "Our meta-analysis justifies the useful addition of cetuximab to standard chemotherapy regimens for mCRC. This approach could improve patient outcomes and provide a valuable addition to current treatment strategies. Future research is needed to confirm its clinical efficacy, identify patient subgroups that are most likely to benefit and explore its impact on survival and quality of life for optimal integration into clinical practice. The findings underscore the cetuximab-chemotherapy combination as a promising first-line protocol for mCRC."

References

1. Azeem, M, Rehman, A, Rasheed, S, et al. The impact of combining cetuximab with the traditional chemotherapy regimens on clinical effectiveness in metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer 25, 331 (2025). Https://doi.Org/10.1186/s12885-025-13515-3

2. Information on cetuximab (marketed as Erbitux). FDA. Updated July 9, 2015. Accessed February 26, 2025. Https://www.Fda.Gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-cetuximab-marketed-erbitux

3. Bonavitacola J. FDA approves encorafenib with cetuximab and mFOLFOX6 for metastatic CRC. AJMC®. December 20, 2024. Accessed February 26, 2025. Https://www.Ajmc.Com/view/fda-approves-encorafenib-with-cetuximab-and-mfolfox6-for-metastatic-crc

---